|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
2
Assay Reproducibility in Hemostasis Diagnostics: Practical Methods to Reduce Variability and Strengthen Trial Outcomes
3
2025 SCRS Global Site Solutions Summit: Best Practices for Building Strong Site Partnerships and Choosing the Right Technology
4
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
